Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis

Changhoon Yoo(Ulsan College), Song Cheol Kim(Ulsan College), Ki Byung Song(Ulsan College), Myung‐Hwan Kim(Korea Aerospace Research Institute), Dae Wook Hwang(Asan Medical Center), Sung Koo Lee(Ulsan College), Kyu‐pyo Kim(Ulsan College), Dong Wan Seo(Dankook University), Baek‐Yeol Ryoo(Asan Medical Center), Sang Hyun Shin(Ulsan College), Tae Jun Song, Jae Hoon Lee(Ulsan College), Sang Soo Lee(Chungbuk National University Hospital), Jin‐hong Park, Jae Ho Jeong(Ulsan College), Jun Kang(Ulsan College), Heung-Moon Chang(Asan Medical Center), Do Hyun Park(Massachusetts Institute of Technology)
Cancers
February 26, 2019
10.3390/cancers11030278
Cited by 40

Related Papers

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
|Proceedings of the National Academy of Sciences|2017|577
TIMP-2 Mediated Inhibition of Angiogenesis
|Cell|2003|510
A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts
|Gastroenterology|2015|472